Invicorp

Phentolamine mesilate and aviptadil, the active ingredient in Invicorp, is a alpha‑adrenergic antagonist and vasoactive intestinal peptide analog presented as a solution for injection for intravenous use. It is employed in clinical settings to modulate vascular tone and inflammatory responses in hospitalized patients.

GNH USA supplies Invicorp as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Invicorp combines two agents that act on vascular and inflammatory pathways, making it suitable for several acute care scenarios.

- Hypertensive emergencies: provides rapid vasodilation to lower dangerously high blood pressure. - Peri‑operative vascular support: helps maintain stable hemodynamics during surgery. - Pulmonary inflammatory conditions: offers bronchodilation and anti‑inflammatory effects in severe respiratory distress.

Invicorp may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Hypotension: transient drop in blood pressure. - Flushing: warm sensation and reddening of skin. - Headache: mild to moderate intensity. - Nausea: occasional gastrointestinal upset. - Tachycardia: increased heart rate. - Injection site pain: local discomfort.

Serious or Rare Side Effects: - Severe hypotension: risk of syncope or organ hypoperfusion. - Cardiac arrhythmias: irregular heart rhythms. - Myocardial ischemia: chest pain due to reduced coronary flow. - Anaphylaxis: acute allergic reaction with airway compromise. - Pulmonary edema: fluid accumulation in lungs. - Severe bronchospasm: worsening respiratory distress.

When using Invicorp, clinicians should observe several safety measures.

- Blood pressure monitoring: check frequently to avoid excessive hypotension. - Cardiac disease caution: avoid in patients with unstable angina or recent myocardial infarction. - Drug interaction vigilance: be careful when co‑administered with other vasodilators or sympathomimetics. - Hypersensitivity assessment: discontinue if signs of allergic reaction appear. - Renal/hepatic function: adjust use in severe impairment as clearance may be altered. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Invicorp can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - MAO inhibitors: may cause unpredictable blood pressure changes. - Other potent vasodilators (e.g., nitroglycerin): risk of profound hypotension. - Beta‑blockers: can mask tachycardia while enhancing hypotensive effect.

Moderate Interactions (Monitor Closely): - Calcium channel blockers: additive blood pressure lowering. - ACE inhibitors or ARBs: may require dose adjustment. - Diuretics: can exacerbate volume depletion. - General anesthetics: may potentiate cardiovascular depression.